NASDAQ:RVLP RVL Pharmaceuticals (RVLP) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free RVLP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.00▼$0.1952-Week Range N/AVolume63.96 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$2.50 Stock AnalysisStock Analysis Get RVL Pharmaceuticals alerts: Email Address Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About RVL Pharmaceuticals Stock (NASDAQ:RVLP)RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.Read More Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! RVLP Stock News HeadlinesMarch 2, 2024 | seekingalpha.comRVLPQ RVL Pharmaceuticals plcJanuary 11, 2024 | morningstar.comRVL Pharmaceuticals PLC RVLPQApril 23, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.October 13, 2023 | marketwatch.comRVL Pharmaceuticals Shares Plummet 50% as Subsidiaries File For BankruptcyOctober 12, 2023 | benzinga.comSpecialty Pharma Firm RVL Pharmaceuticals Subsidiaries File for BankruptcyOctober 12, 2023 | markets.businessinsider.comRVL Subsidiaries To Effectuate Change Of Control; RVLP Ordinary Shares Expected To Be CancelledOctober 12, 2023 | finance.yahoo.comRVL Pharmaceuticals Subsidiaries File for BankruptcyOctober 6, 2023 | investorplace.comWhy Is RVL Pharmaceuticals (RVLP) Stock Up 28% Today?April 23, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.August 23, 2023 | finance.yahoo.comUnmasking the Value Trap: A Deep Dive into RVL Pharmaceuticals PLCAugust 23, 2023 | finance.yahoo.comRVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 21, 2023 | markets.businessinsider.comRVL Pharmaceuticals (RVLP) Gets a Buy from H.C. WainwrightAugust 16, 2023 | benzinga.comCrude Oil Falls Sharply; RVL Pharmaceuticals Shares PlummetAugust 16, 2023 | msn.comRVLP: Second Quarter ResultsAugust 16, 2023 | marketwatch.comRVL Pharmaceuticals Shares Hit New Lows After Stock Sale >RVLPAugust 16, 2023 | msn.comRVL Pharmaceuticals shares fall after pricing $5M stock offeringAugust 16, 2023 | finance.yahoo.comDowngrade: Here's How Analysts See RVL Pharmaceuticals plc (NASDAQ:RVLP) Performing In The Near TermAugust 16, 2023 | finance.yahoo.comRVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesAugust 15, 2023 | finance.yahoo.comQ2 2023 RVL Pharmaceuticals PLC Earnings CallAugust 14, 2023 | msn.comRVLP: Revenue Dip Prompts Spending ReversalAugust 14, 2023 | finance.yahoo.comRVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business ReviewJuly 20, 2023 | finance.yahoo.comInsiders Re-Evaluate Their US$1.6m Stock Purchase As RVL Pharmaceuticals Falls To US$43mJuly 5, 2023 | msn.comRVL Pharma (NASDAQ:RVLP) Rises on Mulling A Strategic TransactionJuly 5, 2023 | benzinga.comRVL Pharmaceuticals shares are trading higher after the company said it has been considering certain strategic alternatives.June 15, 2023 | finance.yahoo.comRVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General MeetingJune 2, 2023 | finance.yahoo.comShareholders in RVL Pharmaceuticals (NASDAQ:RVLP) are in the red if they invested three years agoMay 13, 2023 | finance.yahoo.comTime To Worry? Analysts Just Downgraded Their RVL Pharmaceuticals plc (NASDAQ:RVLP) OutlookSee More Headlines Receive RVLP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RVL Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2023Today4/23/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RVLP CUSIPN/A CIK1739426 Webwww.osmotica.com Phone(908) 809-1300FaxN/AEmployees125Year FoundedN/APrice Target and Rating Average Stock Price Target$2.50 High Stock Price Target$3.00 Low Stock Price Target$2.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$49.72 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / BookN/AMiscellaneous Outstanding Shares111,410,000Free Float106,504,000Market CapN/A OptionableOptionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Brian A. Markison (Age 64)Chairman, President, CEO & Principal Financial Officer Comp: $525kMr. James D. Schaub (Age 41)Executive VP & COO Comp: $367.2kMr. Christopher A. Klein (Age 58)General Counsel & Secretary Comp: $367.2kMr. Michael J. DePetris (Age 46)Principal Accounting Officer Mr. Jarret MillerExecutive Vice President of Human ResourcesKey CompetitorsContext TherapeuticsNASDAQ:CNTXGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPView All CompetitorsInsidersLtd AltchemSold 4,758,899 sharesTotal: $142,766.97 ($0.03/share)Foundation HarsaulSold 3,421,537 sharesTotal: $205,292.22 ($0.06/share) RVLP Stock Analysis - Frequently Asked Questions Should I buy or sell RVL Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for RVL Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" RVLP shares. View RVLP analyst ratings or view top-rated stocks. What is RVL Pharmaceuticals' stock price target for 2024? 1 Wall Street analysts have issued twelve-month target prices for RVL Pharmaceuticals' shares. Their RVLP share price targets range from $2.00 to $3.00. On average, they anticipate the company's share price to reach $2.50 in the next twelve months. View analysts price targets for RVLP or view top-rated stocks among Wall Street analysts. When is RVL Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our RVLP earnings forecast. How were RVL Pharmaceuticals' earnings last quarter? RVL Pharmaceuticals plc (NASDAQ:RVLP) issued its earnings results on Monday, March, 20th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.03. The business had revenue of $9.81 million for the quarter, compared to the consensus estimate of $12.10 million. During the same quarter last year, the company earned ($0.26) earnings per share. This page (NASDAQ:RVLP) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RVL Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
